EUVIMEDEUVIMED entdecken
Crossref

Clinical Outcomes Following Supply‐Driven Transition From Intranasal to Oral Desmopressin in AVP‐Deficiency—A Single Centre Experience Including The Pituitary Foundation Desmopressin Shortage Impact Report

Trevor Tam iD, Amy Mach, Alam Wahid, Neetha Joseph, Amy Shingler, Patricia McBride, Francesca Swords, Ketan Dhatariya, Rupa Ahluwalia iD

Clinical Endocrinology · 2026

DOI: 10.1111/cen.70120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, 2026. Verfasst von Trevor Tam und 8 weiteren Autor:innen. Beteiligte Einrichtung: Norfolk and Norwich University Hospital, Norwich, UK. Hauptthemen laut MEDLINE: Deamino Arginine Vasopressin, Hypopituitarism, Arginine Vasopressin. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Arginine vasopressin deficiency (AVP‐D) requires lifelong desmopressin replacement. In March 2025, the national suspension of intranasal desmopressin necessitated urgent transition to oral alternatives. However, optimal conversion ratios and clinical response remain undefined. We evaluated clinical outcomes following this supply‐driven transition.

Methods

A retrospective study at a tertiary UK centre (01/01/2025–01/07/2025) identified patients with confirmed AVP‐D switched from intranasal to oral desmopressin. Demographic and clinical data were collected. Conversion ratios (intranasal: oral) were calculated before and after titration.

Results

Forty two patients were included (mean age 52.6 ± 2.3; 31% male). 15/42 (35.7%) isolated AVP‐D; 11/42 (26.2%) partial hypopituitarism; 16/42 (38.1%) panhypopituitarism. Median intranasal desmopressin dose pre‐switch was 10 mcg/day (IQR 10–20 mcg). Initial median oral dose before titration was 200 mcg/day (IQR 100–200 mcg); final median oral dose after titration was 200 mcg/day (IQR 162.5–300 mcg). 23/42 (54.8%) were switched initially using 1:10 ratio (10 mcg intranasal desmopressin to 100 mcg oral tablet). 13/23 (56.5%) reported symptomatic recurrence, warranting further titration. The remaining 19/42 (45.2%) were switched initially using a median ratio of 1:20 (IQR 1:11.8–1:20). 10/19 (52.6%) reported symptomatic recurrence. Overall, switching from intranasal to oral desmopressin resulted in 16 patient calls, 79 additional blood tests and one hospitalisation. Similarly, the findings of The Pituitary Foundation Impact Report demonstrated that the switch led to 121/161 (75.2%) of patients reporting poorer symptomatic control post‐switch, and 76/161 (47.2%) requiring additional endocrine input.

Conclusion

45.2% (19/42) of patients achieved adequate symptom control post‐switch with varying conversion ratios, and over half (13/23, 56.5%) of patients switched with an initial 1:10 conversion ratio reported symptomatic recurrence. Although a higher initial conversion ratio closer to 1:15 may reduce symptomatic recurrence in some patients, initiating treatment at a 1:10 ratio with careful up‐titration represents a safe and pragmatic approach that minimises the risk of over‐replacement and hyponatraemia, although inter‐patient variability necessitates tailored titration. In parallel, national patient‐reported data from The Pituitary Foundation Impact Report demonstrate the substantial patient and clinical burden of this supply‐driven switch, highlighting the need for standardised guidance and prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Deamino Arginine VasopressinHypopituitarismArginine VasopressinHumansMaleAdministration, IntranasalRetrospective StudiesFemaleAdministration, OralMiddle AgedTreatment OutcomeAdultAntidiuretic Agents

Stichwörter der Autor:innen

administration, deamino arginine vasopressindiabetes insipidus, neurogenicintranasaloral

Substanzen

Deamino Arginine VasopressinArginine VasopressinAntidiuretic Agents

Autor:innen und Institutionen

  • Norfolk and Norwich University Hospital, Norwich, UK.
  • University of East Anglia, Norwich, UK.
  • The Pituitary Foundation, Bristol, UK.

ORCID-Profile: Trevor Tam, Rupa Ahluwalia

Zitieren

APA

Tam, T., Mach, A., Wahid, A., Joseph, N., Shingler, A., McBride, P., Swords, F., Dhatariya, K., & Ahluwalia, R. (2026). Clinical Outcomes Following Supply‐Driven Transition From Intranasal to Oral Desmopressin in AVP‐Deficiency—A Single Centre Experience Including The Pituitary Foundation Desmopressin Shortage Impact Report. Clinical Endocrinology. https://doi.org/10.1111/cen.70120

Vancouver

Tam T, Mach A, Wahid A, Joseph N, Shingler A, McBride P, et al. Clinical Outcomes Following Supply‐Driven Transition From Intranasal to Oral Desmopressin in AVP‐Deficiency—A Single Centre Experience Including The Pituitary Foundation Desmopressin Shortage Impact Report. Clinical Endocrinology. 2026. doi:10.1111/cen.70120

BibTeX
@article{Tam2026,
  author = {Tam, Trevor and Mach, Amy and Wahid, Alam and Joseph, Neetha and Shingler, Amy and McBride, Patricia and Swords, Francesca and Dhatariya, Ketan and Ahluwalia, Rupa},
  title = {Clinical Outcomes Following Supply‐Driven Transition From Intranasal to Oral Desmopressin in AVP‐Deficiency—A Single Centre Experience Including The Pituitary Foundation Desmopressin Shortage Impact Report},
  journal = {Clinical Endocrinology},
  year = {2026},
  doi = {10.1111/cen.70120}
}
Kostenlos starten →